Opinion|Videos|April 7, 2026
TROP2-Directed ADCs Are Redefining TNBC Management
Author(s)Neil Iyengar, MD, Kelsey Natsuhara, MD
Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, discuss emerging data for TROP2-directed antibody-drug conjugates in metastatic triple-negative breast cancer.
Advertisement
Episodes in this series
Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, review emerging data for TROP2-directed antibody-drug conjugates (ADCs) and their impact on metastatic triple-negative breast cancer (TNBC). The pair highlight key findings from phase 3 trials such as ASCENT-03 (NCT05382299), ASCENT-04 (NCT05382286), and TROPION-Breast02 (NCT05374512) that support the growing role of these agents. They also discuss how these data may position ADC-based regimens as a potential frontline standard for select patients with TNBC.
Advertisement
Related to this article
Komal Jhaveri, MD, FACP, discusses the design of the SERENA-6 trial and larger questions for the breast cancer field that remain after seeing its results.
A study found that the vast majority of veterans with early prostate cancer pursued surveillance instead of treatment.
The oral OMNI-EGFR inhibitor earned fast track status for advanced EGFR C797S–positive non–small cell lung cancer that progressed on a third-generation EGFR TKI.
The oral PARG inhibitor ETX-19477 earned fast track status for BRCA-mutated, HR-positive, HER2-negative unresectable or metastatic breast cancer.
Weekly oral dordaviprone maintenance after allogeneic transplant produced no DLTs and low rates of grade 3/4 cytopenias in high-risk AML and MDS.
An analysis of 12 randomized trials validated MRD-negative CR as a surrogate for PFS in earlier-line relapsed/refractory multiple myeloma.
Sapanisertib and serabelisib plus paclitaxel received FDA fast track designation for pretreated advanced PI3K/AKT/mTOR pathway–altered endometrial cancer.
Lisa Niswander, MD, PhD, of Roswell Park, is investigating ways to combine CAR T cells and a new class of targeted cancer drugs for younger leukemia.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to BH-30643 in EGFR C797S+ NSCLC
2
FDA Grants Fast Track Designation to ETX-19477 in BRCA-Mutated HR+/HER2– Breast Cancer
3
FDA Grants Fast Track Designation to Sapanisertib and Serabelisib Plus Paclitaxel in Advanced Endometrial Cancer
4
Dr Leary on a Neo-Epitope-Based Vaccine With or Without Pembrolizumab in Platinum-Sensitive Recurrent Ovarian Cancer
5